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cally significant (p> .05), a trend toward more days hospitalized from disease-asso-
ciated complications was observed for patients managed with WW (Mean= 9.21, 
respectively) and non-systemic treatment (Mean= 8.27) than patients treated 
with chemotherapy (Mean= 7.25) or TKIs (Mean= 8.22). ConClusions: Among 
patients diagnosed with RRDTC, watch and wait and non-systemic treatment 
options remain common. A large direct cost burden may be observed given the 
frequent and long hospital stays.
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objeCtives: There is increasing pressure on regulators from patients, physicians 
and industry for earlier access to pharmaceuticals for serious diseases. In reaction, 
in March 2014 the European Medicines Agency (EMA) announced it was piloting 
adaptive licensing, and the Medicines and Health care products Regulatory Agency 
(MHRA) unveiled their Early Access to Medicines Scheme. Nevertheless, there are 
questions over how, and if, Phase II trial benefits can be predictive of clinical advan-
tages in Phase III studies, which this research aims to address. Methods: Phase 
III data of any Non-Small Cell Lung Cancer (NSCLC) oncologic appraised by the 
EMA, or that had failed Phase III clinical trials, since 2002 was extracted along with 
its corresponding Phase II data. Statistical tests were conducted using Pearson’s 
coefficient correlation. Results: 12 oncologics were identified with both Phase 
II and III readouts, 6 of which met their Phase III trial primary endpoint. Overall 
Response Rates (ORRs) reported in Phase II trials varied from 0%-61% (mean 24%). 
4/4 (100%) drugs with Phase II ORRs > 30% met their primary endpoint vs. only 
2/8 (25%) with ORRs ≤ 30%. Phase II ORRs were strongly correlated with Phase III 
Progression-Free Survival (PFS) (r2= 0.864, p< 0.0005) and Overall Survival (OS) out-
comes (r2= 0.858, p< 0.001). Nevertheless, 5/6 drugs that failed their Phase III primary 
endpoints had comparative Phase II data indicating benefits versus these same 
comparators, most notably onartuzumab, whose Phase III trial was terminated early 
due to lack of efficacy, despite demonstrating significant OS benefits of 8.8 months 
in Phase II. ConClusions: In NSCLC, Phase II ORRs can be strongly predictive of 
the magnitude of PFS and OS readouts in Phase III trials. However, comparative 
advantages in Phase II trials seem to be poorly predictive of OS benefits in Phase 
III studies, raising questions over the appropriateness of approving drugs on early 
stage comparative data.
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objeCtives: To investigate feasibility and effectiveness of a cervical screening 
program with DNA tests as preliminary assay versus usual cytology protocols in 
Umbria Region. Methods: A large cohort of 35-64 aged women afferent to the 
unique regional laboratory was considered. The usual algorithm with cervical cytol-
ogy as primary test was followed in January 2008–June 2010, whereas in August 
2010–October 2011 high-risk human papillomavirus (HR-HPV) DNA test was used 
as primary screening. The cohorts were compared in terms of acceptance rate of 
invitation, cytological results, molecular results including HPV genotype, detection 
rate of histological lesions. Results: A total of 31,228 women were invited: 21,249 
were suggested to undergo classical cervical cytology screening, 9,979 HR-HPV DNA 
test as primary screening. A similar rate of adhesion (56.6% vs. 56.5%) was observed. 
Age-related differences were evidenced, with younger women (35-49) more prone to 
accept the invitation to HR-HPV DNA testing rather than usual cytology screening 
(61.6% vs. 55.5%; p< 0.0001); analogously, uninvited younger women spontaneously 
requesting cervical screening were more prone to specifically request molecular 
than classical cytological testing (24.8% vs. 10.8%; p< 0.0001). Among the 6,272 
HR-HPV DNA testing women, 396 (6.4%) were positive, and, among them, 141 (36%) 
featured an altered cytology. All patients with altered cytology were suggested to 
undergo colposcopy and 106 out of 141 (75.1%) answered to the invitation. Among 
them, 89 (84%) featured abnormal histology with 48 (45.3%) CIN1 and 41 (38.7%) 
CIN2. If comparing the CIN2 detection rate within the two studied periods, it was 
almost doubled using the HR-HPV DNA than pap test as primary assay (0.64% vs. 
0.37%; p= 0.005). Finally, the implementation of the DNA test screening program did 
not increase total costs. ConClusions: Although with some limits, the introduc-
tion of HR-HPV DNA primary testing resulted feasible and effective, significantly 
increasing detection of severe lesions.
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objeCtives: Prognosis for relapsed or refractory (R/R) MCL patients with existing 
treatments is poor; most patients progress within ~4 months. Ibrutinib, an oral once 
daily Bruton’s tyrosine kinase inhibitor showed durable single agent activity with 
good response rate in 111 R/R MCL patients and a median progression free survival 
(PFS) of 13.9 months. Ibrutinib received breakthrough designation and United States 
Food and Drugs Administration approval for use in MCL patients who received at 
least one prior therapy (R/R MCL). This indirect analysis aims to compare the efficacy 
Systematic searches in the electronic databases MEDLINE, EMBASE and The 
Cochrane library were conducted and 53 online databases (including HTA agency 
websites, international ministries of health, and clinical trials. gov) were hand 
searched for clinical guidelines in the treatment of MO caused by RVO. Results: 
Fifteen documents on treatment pathways or guidance used internationally were 
identified from the hand searches. No papers or abstracts were found from the 
electronic database searches. There were considerable between-jurisdiction dif-
ferences in the guidance for the management of MO caused by RVO. These differ-
ences were consolidated to produce two amalgamated treatment pathways. In 
total, eight treatment positions for interventions in the treatment of RVO subtypes 
were identified. For one of the identified positions – treatment of ischaemic branch 
RVO – no licensed treatment currently exists. ConClusions: The described sys-
tematic methodology for the construction of treatment pathways may be used 
by manufacturers in early drug development decisions to identify unmet clini-
cal needs, understand which treatment positioning may provide the most value, 
and identify future treatment comparators in the same indication. Guidelines 
to inform such commercial strategies may not be identifiable from electronic 
database searches alone with extensive hand searches being a necessity. Between 
jurisdiction guideline nuances also need to be taken into account when consider-
ing the target market for an intervention in development.
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objeCtives: Ophthalmology pharmaceutical market is growing worldwide due 
to rising aging population, new delivery technologies and changing lifestyle. 
However, challenges like patent expiry of major brands and lack of awareness 
still persists. Therefore, it is important to be aware of the upcoming treatment 
options, changing patients’ needs and requirement of cost effective therapies. 
This analysis provides an overview of the recent trends and future scenario in 
Ophthalmology market. Methods: Pharmaceutical companies sponsored clinical 
trials initiated from January 2011 to April 2014 in Glaucoma, Age-related Macular 
Degeneration (AMD), Diabetic Retinopathy (DR) / Diabetic Macular Edema (DME), 
Dry eye syndrome (DES) and Retinal vein occlusion (RVO) have been considered. 
Only Phase I - III trials listed on public registries have been considered. Results: 
The data showed that > 30% of the trials are being conducted on Glaucoma in 
USA, Europe, Asia and Australia. This is followed by AMD (24%), DR/DME (21%), 
DES (17%) and RVO (7%). Also, > 50% ophthalmological trials are being conducted 
in USA; followed by Europe (~25%) and Asia (~20%). In Europe, 71 trials have been 
conducted on 48 molecules, of which 69% are chemical entities, 19% are biologicals 
and > 10% are entities like RNAi (oligonucleotide, aptamers), DARPin. Eye drops 
(46%) and intravitreal injections (37%) are the key topical and parenteral formula-
tions, respectively. 10% of the trials have been conducted on oral formulations. In 
Europe, EU5 countries comprise of 43% of the trials and Germany has maximum 37 
trials. Novartis has conducted trials in maximum 30 countries, followed by Santen 
(19), Pfizer (15) and Allergan (13) in Europe. ConClusions: Based on the analysis, 
currently, Glaucoma, AMD and DR/DME are the major focus of the companies in 
ophthalmology. Though, biologicals and RNAi are being tested routinely, chemical 
entities are foremost modalities. Similarly, eye drops remain as preferred method 
of delivery with respect to other newer delivery techniques.
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objeCtives: Most patients with differentiated thyroid cancer (DTC) have an 
excellent prognosis after receiving standard treatment, consisting of surgery and 
often adjuvant radioactive iodine (RAI). However, a subgroup of patients prove to 
have progressive DTC which is refractory to RAI (RRDTC). Treatment options for 
RRDTC are limited. This study investigated the treatment patterns and health care 
resource utilization of patients with RRDTC. Methods: Data were collected by 
performing a retrospective chart review study in the US and 5EU (France, Germany, 
Italy, Spain, UK) with physicians recruited from an online panel. Physicians pro-
vided clinical information on 1 to 4 of their RRDTC patients in an online survey. 
Demographics, disease history, treatment information, and health care resource 
were included and reported descriptively. Health care resource use was compared 
across treatment classes using general linear models. Results: 231 physicians 
participated and provided a total of 700 patient charts (44.1% of charts were from 
the US and 11-12% from each 5EU country). 45.0% of patients were male with a 
mean age at diagnosis of 55.1 years [SD= 12.4]. 52.0% of patients were treated 
with systemic treatment (e.g., 16.9% tyrosine kinase inhibitors [TKIs] only; 13.3% 
chemotherapy only). The remaining 48.0% were either in a watch and wait (“WW”) 
period (20.1%) or were managed with non-systemic palliative therapies (27.9%; eg, 
external beam radiation). Overall, patients averaged 15.87 days hospitalized per 
year (due to disease related complications or side effects). Although not statisti-
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objeCtives: Lung cancer is one of the most common causes of cancer-related 
deaths world-wide. Afatinib is an irreversible ErbB family blocker showing superior 
efficacy in EGFRm+ NSCLC as 1st-line treatment compared to standard-of-care 
chemotherapy. To date, no head-to-head trial results exist to compare afatinib, gefi-
tinib or erlotinib. Previous NMAs have compared the three treatments on an ITT 
level, but not by mutation type. This analysis attempts to fill this gap. Methods: 
Based on the EGFRm+ study network requested by NICE a Bayesian approach NMA 
was conducted to estimate relative treatment effects of afatinib versus erlotinib and 
gefitinib for progression free survival (PFS) and overall survival (OS) per mutation 
type (common mutations: Del19 and L858R). Results: 9 studies were included, 
8 reported PFS and 5 OS by mutation type, respectively. Results from fixed effects 
models are reported. Afatinib significantly improved PFS in common mutations 
versus gefitinib (HR 0.43: CrI 0.24; 0.75) and erlotinib (HR 0.60; CrI 0.39; 0.91). Results 
also favored afatinib for both EGFR mutation subgroups Del19 and L858R, but did 
not reach statistical significance. Afatinib showed a high probability (> 80%) of being 
the best treatment both for common mutations and per mutation type. For OS, a 
trend favoring afatinib was shown in particular for Del19. The probability of afatinib 
being best for Del19 was > 70%. For L858R no difference in OS was detected between 
the TKIs. ConClusions: In line with findings from previous NMAs, this analysis 
by mutation type confirms both for PFS and OS a consistent trend towards supe-
riority of afatinib versus reversible TKIs. Afatinib appears to be the best treatment 
option for patients with common mutations, in particular Del19 mutations. A direct 
trial-based comparison of the efficacy of these agents is warranted to clarify their 
relative benefits.
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objeCtives: This analysis described health care costs over time—excluding ipili-
mumab drug costs—stratified by survival duration and baseline ECOG status, in 
patients receiving ipilimumab for advanced melanoma in the US community set-
ting. Methods: We analyzed data from a retrospective chart review of patients 
with unresectable stage III/IV melanoma treated with ipilimumab as first-line 
monotherapy between 04/2011 and 09/2012. Hospitalizations, emergency depart-
ment visits, subsequent chemotherapy, radiation, surgeries, nursing home, and 
hospice visits costs were estimated using published sources and tariffs. Total costs, 
excluding ipilimumab drug costs, were calculated for 3 periods: treatment regimen 
(between first and last ipilimumab doses); post-regimen; and pre-death (within 90 
days of death). Monthly costs were compared for the total population and stratified 
by baseline ECOG status (0 vs. ≥ 1, when available) and survival (< 1 year vs. ≥ 1 year) 
using Wilcoxon rank sum tests. Results: Data were abstracted from 273 patient 
charts at 34 sites. Excluding ipilimumab drug costs, total monthly costs during the 
treatment regimen, post-regimen, and pre-death periods were $690, $2151, and 
$5123, respectively. Total monthly costs across all study periods were higher for 
patients with ECOG ≥ 1 (n= 135) vs. ECOG= 0 (n= 104) (p= 0.0294), particularly in the 
pre-death period ($5987 vs. $3460, respectively; p= 0.0143). A similar pattern was 
observed for patients surviving < 1 year (n= 109) vs. ≥ 1 year (n= 122) (p< 0.0001), with 
a difference of $9524 vs. $2955 (p< 0.0001) during the pre-death period (42 patients 
still alive after < 1 year follow-up were excluded from this analysis). Key cost drivers 
were hospitalizations (32.4% of total costs), followed by non-ipilimumab chemother-
apy (23.1%), hospice care (19.1%), and nursing home stays (12.5%). ConClusions: 
In this population, monthly costs were significantly lower during the treatment 
regimen period than in subsequent periods. Survival ≥ 1 year and baseline ECOG= 0 
were associated with significantly lower total monthly costs, particularly in the 
pre-death period.
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objeCtives: No standard of care exists for patients with relapsed or refractory 
mantle cell lymphoma (MCL) and treatment options are limited. This study sought 
to synthesize the clinical evidence of current treatments for relapsed or refractory 
MCL, its limitations, and discuss the implications for decision making. Methods: 
A systematic literature review was conducted in MEDLINE of phase II, III, or IV 
clinical trials published in English between January 1, 2001 and May 2, 2013. 
Supplemental searches included EHA, AACR, ASCO, and ASH 2011–2013 confer-
ence proceedings. Results: Results of the review indicate a paucity of evidence 
relevant for decision making. Of 808 records reviewed, 17 trials in the R/R MCL 
population were identified, only three of which were randomized controlled trials; 
all others were single-arm trials. For most treatments, only one trial was available. 
These factors made it infeasible to conduct a meta-analysis or indirect comparison. 
Furthermore, there was a large amount of heterogeneity in the patient popula-
tions, trial designs, and reported outcomes, making it difficult to compare outcomes 
across trials. Finally, of the 17 trials identified, five reported progression-free sur-
vival (PFS) Kaplan–Meier (K-M) graphs and only three reported overall survival (OS) 
of ibrutinib to available treatments for R/R MCL patients. Methods: A systematic 
literature review was conducted to identify clinical trials containing treatments of 
R/R MCL. Matching adjusted indirect comparison (MAIC), described by Signorovitch 
et al 2012, was utilized to obtain indirect relative treatment effect for ibrutinib 
compared to other treatments. Using individual patient level data (IPD), baseline 
characteristics of the ibrutinib trial patients were matched with the patients in the 
published studies to obtain overall response (ORR) and complete response (CR) rates 
based on balanced population between the ibrutinib and published studies. Kaplan 
Meir curves for overall survival and PFS of comparators were plotted alongside those 
of the matched ibrutinib patients. Results: Nineteen studies evaluating various 
treatments were identified. Five trials evaluating bortezomib, BR (bendamustine, 
rituximab), FCM (fludarabine, cyclophosphamide, mitoxantrone), FCM-R (fludara-
bine, cyclophosphamide, mitoxantrone, rituximab), and rituximab-hyper-CVAD 
were considered for matching. Complete matching of the IPD was possible for the 
bortezomib, FCM and FCM-R studies. Ibrutinib showed statistically significant bet-
ter odds of achieving ORR compared to bortezomib (OR 3.62; 95% CI 1.18-11.14) and 
FCM (OR 3.22; 95% CI 1.01-10.26). ConClusions: The indirect analysis suggests a 
potential for improved ORR compared to a few relevant treatments in patients with 
R/R MCL. Phase III comparative confirmatory data with ibrutinib are anticipated 
in late 2014.
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objeCtives: The NSABP/NCCTG trial (Romond et al. NEJM 2005; 353: 1673-1684) 
established the efficacy of trastuzumab in the adjuvant treatment of HER2+ early 
stage breast cancer (HER2+BC). Yet, little is known about the patterns of use and 
outcomes of adjuvant trastuzumab in clinical practice. The study aimed to esti-
mate the overall survival (OS) and relapse-free survival (RFS) of HER2+BC patients 
treated with adjuvant trastuzumab in the US Department of Defense (DOD) prac-
tice setting. Methods: Adult women initiating adjuvant trastuzumab within 1 
year of BC surgery were identified in the DOD health claims database (01/2003-
12/2012). An algorithm based on secondary neoplasm ICD9 codes and treatment 
gaps and initiations was used to identify relapses. OS and RFS unadjusted rates 
at 3 and 4 years after the initiation of the adjuvant trastuzumab treatment were 
estimated from Kaplan-Meier plots. Results: The study sample included 3,188 
women (median age 63 years), followed for a median of 3.3 years after the initia-
tion of trastuzumab and treated continuously with trastuzumab for a median of 
12 months. Of these 3,188 women, 13.8% received neo-adjuvant therapy prior to 
the surgery, 17.7% relapsed, and 7.9% died during the follow-up. The OS rates at 3 
and 4 years were 93.2% (95% CI 92.1%-94.2%) and 90.0% (88.6%-91.2%), respectively. 
The corresponding RFS rates were 78.8% (77.1%-80.3%) and 75.8% (74.0%-77.5%), 
respectively. ConClusions: The findings suggest that most HER2+BC patients in 
the DOD practice setting received per-label trastuzumab treatment (for 52 weeks) 
and had OS rates that are similar to the OS rates that were previously observed 
in the NSABP/NCCTG clinical trial (90.0% vs. 93% at four years). The lower RFS 
rates observed in this study versus the NSABP/NCCTG trial (75.8% vs. 85.7% at 
4 years), may be partially explained by differences in the characteristics of the 
patients, including age.
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objeCtives: To assess the relative efficacy of first-line treatments in chronic mye-
loid leukaemia (CML), an updated systematic literature review (SLR) and indirect 
comparison (IC) were conducted with follow-up period up to 48 months. Methods: 
We updated a SLR initially conducted in 2011. Medical databases were interrogated 
systematically in January 2014 to identify trials comparing first-line treatments for 
CML. Using a fixed-effect Bayesian model implemented in WinBUGS, ICs were made 
to calculate relative efficacy (cumulative complete cytogenetic response (CCyR) and 
major molecular response (MMR)) for dasatinib, nilotinib and imatinib. Results: 
Nineteen randomised controlled trials (RCTs) were included in the SLR, 10 were 
eligible for inclusion in the IC. Compared with imatinib 400mg by 12 months, odds 
of cumulative CCyR were significantly greater for dasatinib 100mg [odds ratio (OR) 
2.25,95% credible interval (CrI) 1.55-3.15], nilotinib 600mg [OR 2.23 (95% CrI 1.50-
3.21)] and 800mg [OR 1.94 (95% CrI 1.31-2.78)]. By 24 months compared with imatinib 
400mg, the odds remained significantly higher with nilotinib 600mg [OR 2.03 (95% 
CrI 1.28-3.10)] and 800mg [OR 1.70 (95% CrI 1.08-2.55)] and higher, but not signifi-
cant with dasatinib 100mg [OR 1.41 (95% CrI 0.85-2.22)]. By 12,24,36 and 48 months 
respectively, compared with imatinib 400mg, the odds of a MMR were: dasatinib 
100mg [OR 2.22 (95% CrI 1.52-3.15) / 2.09 (1.45-2.93) / 1.76 (1.22-2.48) / 1.90 (1.27-2.74)] 
nilotinib 600mg [OR 2.86 (95% CrI 1.95-4.08) / 3.24 (2.26-4.54) / 2.45 (1.70-3.43) / 2.54 
(1.75-3.59)] and 800mg [OR 2.76 (95% CrI 1.88-3.94) / 2.60 (1.82-3.62) / 2.12 (1.48-2.95)/ 
2.18 (1.51-3.06)]. For both outcomes at all time points, there was no significant differ-
ence between dasatinib and nilotinib. ConClusions: Analysis including all avail-
able RCTs suggests that second-generation tyrosine kinase inhibitors dasatinib and 
nilotinib are more efficacious than imatinib 400mg and should be treatments of 
choice in newly diagnosed CML.
